LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Apellis Pharmaceuticals Inc

Open

SectorHealthcare

19.31 1.79

Overview

Share price change

24h

Current

Min

19.06

Max

19.69

Key metrics

By Trading Economics

Income

-56M

-92M

Sales

-46M

167M

EPS

-0.74

Profit margin

-55.292

Employees

705

EBITDA

-56M

-80M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+91.63% upside

Dividends

By Dow Jones

Next Earnings

31 Jul 2025

Market Stats

By TradingEconomics

Market Cap

-191M

2.4B

Previous open

17.52

Previous close

19.31

News Sentiment

By Acuity

71%

29%

348 / 380 Healthcare

Apellis Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

5 Jun 2025, 20:45 UTC

Earnings

Broadcom 2Q Sales Climb on Booming AI Demand

5 Jun 2025, 23:45 UTC

Market Talk

Nikkei May Decline as Caution Over U.S. Economy Continues -- Market Talk

5 Jun 2025, 23:44 UTC

Market Talk

Gold Edges Higher on Weak U.S. Data -- Market Talk

5 Jun 2025, 23:30 UTC

Market Talk

NZME Cost Cuts Can Cushion Effect of Weak Market -- Market Talk

5 Jun 2025, 21:32 UTC

Earnings

Broadcom Stock Falls Despite Earnings Beat From AI Chip Maker -- Barrons.com

5 Jun 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

5 Jun 2025, 20:45 UTC

Earnings

Broadcom Stock Falls Despite Earnings Beat From AI Chip Maker -- Barrons.com

5 Jun 2025, 20:24 UTC

Earnings

Broadcom Stock Falls Despite Earnings Beat From AI Chip Maker -- Barrons.com

5 Jun 2025, 20:15 UTC

Earnings

Broadcom 2Q Cont Ops EPS $1.03 >AVGO

5 Jun 2025, 20:15 UTC

Earnings

Broadcom 2Q Rev $15B >AVGO

5 Jun 2025, 20:15 UTC

Earnings

Broadcom 2Q Net $4.97B >AVGO

5 Jun 2025, 20:15 UTC

Earnings

Broadcom 2Q Adj EPS $1.58 >AVGO

5 Jun 2025, 20:15 UTC

Earnings

Broadcom 2Q EPS $1.03 >AVGO

5 Jun 2025, 20:15 UTC

Earnings

Broadcom Sees 3Q Rev $15.8B >AVGO

5 Jun 2025, 20:11 UTC

Acquisitions, Mergers, Takeovers

Constellation Energy: Transaction Is Expected to Close in the 4Q >CEG

5 Jun 2025, 20:11 UTC

Acquisitions, Mergers, Takeovers

Constellation Energy: Calpine Deal Clears Texas Regulatory Review

5 Jun 2025, 20:11 UTC

Acquisitions, Mergers, Takeovers

Constellation Energy: With Approval From PUCT Secured, Transaction Awaits Clearance From NY State Public Service Commission, Federal Energy Regulatory Commission and DOJ >CEG

5 Jun 2025, 19:22 UTC

Market Talk

Oil Futures Resume Upward Moves -- Market Talk

5 Jun 2025, 19:00 UTC

Market Talk

U.S. Natural Gas Settles Lower in Choppy Trade -- Market Talk

5 Jun 2025, 18:32 UTC

Market Talk

Gold Slips After Trump-Xi Call -- Market Talk

5 Jun 2025, 18:26 UTC

Earnings

These Stocks Are Moving the Most Today: Broadcom, Tesla, Circle, Brown-Forman, MongoDB, Planet Labs, ChargePoint, Ciena, and More -- Barrons.com

5 Jun 2025, 18:06 UTC

Market Talk

Transpacific Ship Freight Rates Spike on China Tariff Truce -- Market Talk

5 Jun 2025, 16:30 UTC

Acquisitions, Mergers, Takeovers

Vallourec Completes The Acquisition Of Thermotite Do Brasil >VK.FR

5 Jun 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

5 Jun 2025, 16:18 UTC

Market Talk

U.S. Natural Gas Market Shrugs Off Big Storage Build -- Market Talk

5 Jun 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

5 Jun 2025, 16:12 UTC

Market Talk

Global Energy Roundup: Market Talk

5 Jun 2025, 16:12 UTC

Market Talk

Copper Prices Rise on Positive Signals From Trump on China Trade Talks -- Market Talk

5 Jun 2025, 16:03 UTC

Market Talk

U.S. Diesel, Gasoline Futures Pick Back Up -- Market Talk

5 Jun 2025, 15:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

Peer Comparison

Price change

Apellis Pharmaceuticals Inc Forecast

Price Target

By TipRanks

91.63% upside

12 Months Forecast

Average 35.47 USD  91.63%

High 57 USD

Low 18 USD

Based on 19 Wall Street analysts offering 12 month price targets forApellis Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

19 ratings

11

Buy

8

Hold

0

Sell

Sentiment

By Acuity

348 / 380 Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.